醫藥股普遍逆美股同業受壓 北海康成(01228.HK)及來凱醫藥(02105.HK)挫12%-17%
美股的醫藥板塊於2024年首個交易日跑贏大市,莫德納(MRNA.US)重申2025年實現銷售增長目標後,獲券商Oppenheimer升級至「跑贏大市」,刺激該股昨晚急升13.1%,盤後再升2.1%報114.9美元。輝瑞(PFE.US)繼昨晚升3.3%後,盤後再升0.3%報29.82美元。BioNTech(BNTX.US)昨晚於納指ADR升6.5%,盤後再升1.5%報114.08美元。藍籌默克(MRK.US)及安進(AMGN.US)昨晚分別升3.9%及3.3%,收113.24美元及297.39美元,爲表現最好的道指成份股。
然而,本港醫藥股今天普遍隨大市受壓,尤其是「B仔股」沽壓沉重,北海康成-B(01228.HK)表現最差,股價三連跌,低見0.8元,現報0.82元,下挫17%,成交只有2.9萬股。
來凱醫藥-B(02105.HK)四連跌,股價曾挫15%至14.38元,現報14.9元,下挫12%,成交倍增至179萬股,創兩個月高。
康諾亞-B(02162.HK)兩連跌,最低見43.85元,現報44.75元,續跌3.8%。康方生物(09926.HK)及鷹瞳科技-B(02251.HK)低見43.85元及10.9元,現報44.45元及11.06元,續跌2.7%及3.2%。
信達生物(01801.HK)、泰格(03347.HK)、金斯瑞生物(01548.HK)、榮昌生物(09995.HK)及威高股份(01066.HK)續跌逾3%-4%,後者沽壓最大。
恆指繼今早續跌至16,564守穩20天線後,下午跌幅收窄至165點或1%,報16,622,總成交額541億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.